Roche gets FDA okay for transplant patients Epstein-Barr virus test

Credit: REUTERS/Arnd Wiegmann

ZURICH, Aug 5 (Reuters) - Roche ROG.S has received authorisation from the United States' Food and Drug Administration (FDA) for its cobas 6800/8800 diagnostic tests for transplant patients, the company said on Wednesday.

The tests are used to detect Epstein-Barr virus DNA levels, linked to a range of diseases including cancer. The tests had previously been granted a breakthrough device designation by the FDA.

(Reporting by John Revill; Editing by Kim Coghill)

((; +41 58306 7022; Reuters Messaging:

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


More Related Articles

Info icon

This data feed is not available at this time.

Sign up for Smart Investing to get the latest news, strategies and tips to help you invest smarter.